QNRX News and Press, Quoin Pharmaceuticals Ltd. From 05/17/22

Quoin Pharmaceuticals (QNRX) is developing a potential treatment for a patient population in desperate need. We spoke with CEO, Dr. Michael Myers, to find out more about Netherton Syndrome, a rare and devastating genetic disease. New York, New York--(Newsfile Corp. - May 17, 2022) - PCG Digi...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s the final day of trading this week and it begins with a deep dive into the biggest pre-market stock movers for Friday! Source: f11photo/Shutterstock.com We’re still in the thick of earnings season...

While 2022 might be the ‘year of the active trade,’ it is also continuing the ‘era of the meme stonk’ to some extent. We all remember how exciting it was for beaten-down penny stocks in 2020 and 2021. Shares of companies like AMC Entertainment ( NYSE: A...

Gainers: Nkarta (NKTX) +84%. ERYTECH Pharma (ERYP) +54%. Sunshine Biopharma (SBFM) +25%. Rubius Therapeutics (RUBY) +17%. Quoin Pharmaceuticals (QNRX) +12%. Losers: Eliem Therapeutics (ELYM) -55%. Clarus Therapeutics Holdings (CRXT) -54%....

American depositary shares of Quoin Pharmaceuticals (NASDAQ:QNRX) have added 45.7% in premarket trading on Monday after the U.S. Food and Drug Administration cleared the company's new drug application for its investigational lotion QRX003 to treat skin disorder Netherton Syndrome. The company...

ASHBURN, Va., April 25, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has received U.S. Food and Drug Administration (...

Quoin Pharmaceuticals (NASDAQ:QNRX) plans to seek regulatory approval for its lead candidate QRX003 for Netherton Syndrome (NS) in 2024, the company’s Chief Operating Officer Denise Carter disclosed in an interview on Thursday. NS is a rare skin disorder without no approved therapy. It...

As company (QNRX) gains strength, Chief Operating Officer, Denise Carter, talks about what's next for Quoin New York, New York--(Newsfile Corp. - March 24, 2022) - PCG Digital -- Netherton Syndrome (NS) is a rare and devastating skin disease that is estimated to affect between 2,000 and 4,000...

Gainers: JX Luxventure (LLL) +214%. Draganfly (DPRO) +83%. Zhangmen Education (ZME) +64%. Antelope Enterprise Holdings Limited (AEHL) +37%. Society Pass (SOPA) +31%. Ever-Glory International Group (EVK) +33%. iQIYI (IQ) +26%. Alzamend Neuro (ALZN) +23%. FreightCar America (RAIL) +24%. Puxin (...

Quoin Pharmaceuticals (NASDAQ:QNRX) submitted an investigational new drug application to the U.S. Food and Drug Administration to begin clinical trial of topical lotion QRX003 for Netherton Syndrome (NS). NS is a rare genetic disorder characterized by scaling skin, hair anomalies and inc...